Grace Therapeutics, Inc.
Business
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel drug delivery formulations for rare and orphan diseases. The company applies proprietary formulation and nanoparticle technologies to existing, approved pharmaceutical compounds to improve efficacy, safety, and patient compliance. Its lead candidate, GTx-104, is an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage; the company also retains intellectual property for GTx-102 (for ataxia-telangiectasia) and GTx-101 (for postherpetic neuralgia), though internal development of these candidates has been halted. Grace is pursuing U.S. regulatory approval via the Section 505(b)(2) pathway and plans hospital-based commercialization if approved, with potential international partnerships.
Summary from 10-K filed 2026-06-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Research and development expenses | 2 | 10 | −5 | −10 | −6 | |
| General and administrative expenses | 9 | 7 | −7 | −8 | −9 | |
| Loss from operating activities | −11 | −17 | −13 | −52 | −16 | |
| Foreign exchange loss | −1,000 | −17,000 | −16,000 | −72,000 | — | |
| Change in fair value of derivative warrant liabilities | 900,000 | 3 | −3 | 10,000 | — | |
| Interest and other income, net | 685,000 | 711,000 | 911,000 | 246,000 | — | |
| Total other income, net | 2 | 4 | −2 | 184,000 | 5 | |
| Loss before income tax benefit | −9 | −13 | −15 | −52 | −10 | |
| Income tax benefit | 2 | 3 | 2 | 10 | 648,000 | |
| Net loss | −8 | −10 | −13 | −42 | −10 | |
| Total comprehensive loss | −8 | −10 | −13 | — | — | |
| Basic loss per share (in Dollars per share) | −0.47 | −0.79 | −1.35 | −5.71 | −0.27 | |
| Diluted loss per share (in Dollars per share) | −0.47 | −0.79 | −1.35 | −5.71 | −0.27 | |
| Weighted average number of shares outstanding, basic (in Shares) | 17 | 12 | 10 | 7 | 37 | |
| Weighted average number of shares outstanding, diluted (in Shares) | 17 | 12 | 10 | 7 | 37 |
Consolidated Balance Sheet
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 17 | 22 | 23 | 28 | 30 | |
| Receivables | 20,000 | 126,000 | 722,000 | — | — | |
| Prepaid expenses | 383,000 | 453,000 | 283,000 | 598,000 | 720,000 | |
| Total current assets | 17 | 23 | 24 | 29 | 45 | |
| Equipment, net | 8,000 | 15,000 | 24,000 | 104,000 | 250,000 | |
| Intangible assets | 41 | 41 | 41 | 41 | 70 | |
| Goodwill | 8 | 8 | 8 | 8 | 13 | |
| Total assets | 67 | 72 | 73 | 79 | 129 | |
| Trade and other payables | 2 | 2 | 2 | 3 | 3 | |
| Total current liabilities | 2 | 2 | 2 | 3 | 3 | |
| Derivative warrant liabilities | 0 | 1 | 4 | — | — | |
| Deferred tax liability | 612,000 | 2 | 6 | 7 | 17 | |
| Total liabilities | 3 | 5 | 12 | 11 | 20 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2026 and 2025 | 0 | 0 | 0 | — | — | |
| Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,024,026 and 13,718,106 shares issued and outstanding as of March 31, 2026 and 2025, respectively | 1,000 | 1,000 | 1,000 | 258 | 258 | |
| Additional paid-in capital | 298 | 293 | 279 | 14 | 12 | |
| Accumulated other comprehensive loss | −6 | −6 | −6 | −6 | −6 | |
| Accumulated deficit | −228 | −221 | −211 | −198 | −156 | |
| Total stockholders equity | 64 | 67 | 62 | 68 | 108 | |
| Total liabilities and stockholders equity | 67 | 72 | 73 | 79 | 129 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 7,000 | 7,000 | 11,000 | 124,000 | 0 | |
| Loss on disposal | 0 | 2,000 | 39,000 | — | — | |
| Stock-based compensation | 798,000 | 730,000 | 913,000 | 2 | 1 | |
| Receivables | 106,000 | 596,000 | 80,000 | −302,000 | — | |
| Prepaid expenses | 70,000 | −170,000 | 315,000 | 72,000 | — | |
| Trade and other payables | 543,000 | −84,000 | −2 | 411,000 | — | |
| Net cash used in operating activities | −9 | −15 | −12 | −16 | −17 | |
| Maturity of short-term investments | 0 | 15,000 | 7 | 18 | 31 | |
| Purchase of short-term investments | 0 | −15,000 | −7 | −5 | −35 | |
| Net cash provided by investing activities | 0 | 0 | 104,000 | 13 | −4 | |
| Gross proceeds from issuance of common stock and warrants from private placement | 0 | 15 | 8 | — | — | |
| Stock issuance costs | −327,000 | −967,000 | −162,000 | — | — | |
| Proceeds from issuance of common stock from common warrant exercise | 4 | 0 | — | — | 0 | |
| Net cash provided by financing activities | 4 | 14 | 7 | 304,000 | 0 | |
| Net decrease in cash and cash equivalents | −5 | −872,000 | −5 | −2 | −21 | |
| Issuance costs in accounts payable | 0 | 327,000 | — | — | — | |
| Settlement of derivative warrant liability | 241,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Grace Therapeutics, Inc.'s CIK number?
Grace Therapeutics, Inc.'s SEC CIK number is 0001444192 (1444192). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Grace Therapeutics, Inc.'s SEC filings?
All of Grace Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Grace Therapeutics, Inc. last report earnings?
Grace Therapeutics, Inc. (GRCE) most recently filed an earnings 8-K with the SEC on Jun 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001140361-26-025667). This is Grace Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Grace Therapeutics, Inc.'s most recent earnings 8-K?
Grace Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Jun 18, 2026 under accession 0001140361-26-025667. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Grace Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →